Poliomyelitis, more commonly known as polio, is a devastating disease that can lead to irreversible paralysis, particularly in children under the age of five. This highly infectious disease is caused by the poliovirus, which primarily spreads through contaminated water and food, or direct contact with an infected person. Over the past few decades, concerted global efforts have brought the world close to eradicating polio. However, recent developments in India highlight the ongoing challenges in the fight against this virus, including the emergence of rare cases linked to the very vaccines designed to prevent the disease.

Recently, the World Health Organization (WHO) began investigating a case of poliomyelitis in a two-year-old child from Tikrikilla, located in the West Garo Hills district of Meghalaya. This case has sent shockwaves through the health community in India, a country that was declared polio-free in 2014. The child’s case has been identified as vaccine-derived poliovirus (VDPV), a rare occurrence that has put both state and national health officials on high alert.

Vaccine-derived poliovirus cases are extremely rare but can occur when the weakened strain of the poliovirus contained in the oral polio vaccine (OPV) mutates and regains its ability to cause disease. This situation is a stark reminder that while India has made tremendous strides in eradicating wild poliovirus, continued vigilance is required to maintain its polio-free status.

Polio is caused by the poliovirus, which attacks the nervous system and can lead to paralysis in one out of every 200 infections. The virus is most commonly transmitted through the fecal-oral route, meaning it spreads through food or water contaminated with the feces of an infected person. Although anyone can contract polio, it disproportionately affects young children who have not been vaccinated.

Symptoms of polio can vary, ranging from mild flu-like symptoms such as fever, fatigue, vomiting, and headaches, to more severe manifestations such as muscle pain, stiffness, and in severe cases, paralysis. The paralysis usually affects the legs and is irreversible. In extreme cases, polio can lead to death if the muscles involved in breathing become paralyzed.

The global fight against polio has been one of the most successful public health initiatives in history. Since the launch of the Global Polio Eradication Initiative (GPEI) in 1988, the incidence of polio has dropped by more than 99%. Wild-type poliovirus has been eliminated in most countries, with the virus now endemic in only two countries: Pakistan and Afghanistan. India, once considered the epicenter of polio cases, was declared polio-free in 2014, following an aggressive vaccination campaign that reached millions of children across the country.

This remarkable achievement was largely made possible through the Pulse Polio Immunisation Programme, launched in 1995. This program aimed to vaccinate every child under the age of five, regardless of their previous vaccination status. Through the combined efforts of healthcare workers, policymakers, and community volunteers, the program achieved widespread coverage and drastically reduced the number of polio cases in India.

Polio prevention hinges on vaccination, and there are two main types of vaccines used: the oral polio vaccine (OPV) and the inactivated polio vaccine (IPV). OPV, which is administered orally, contains a live but weakened form of the virus. This type of vaccine has been instrumental in reducing polio cases worldwide because it is easy to administer and provides good immunity. However, in rare cases, the weakened virus in the OPV can mutate and revert to a form that can cause paralysis, leading to vaccine-derived poliovirus cases.

IPV, on the other hand, is administered via injection and contains an inactivated (killed) virus. IPV is effective against all three serotypes of poliovirus and does not carry the risk of mutation that OPV does. However, because it requires trained healthcare professionals to administer and is more expensive, IPV is less commonly used in mass immunization campaigns in developing countries.

The recent case in Meghalaya raises questions about the continued use of OPV in India. While the OPV has been crucial in eradicating wild poliovirus, the risk, albeit small, of vaccine-derived cases has led some experts to advocate for a transition to IPV. Dr. Rakesh Mishra, Director at the Tata Institute for Genetics and Society, suggests that India may need to reconsider its reliance on OPV, especially now that wild poliovirus has been eradicated in the country.

Vaccine-derived poliovirus occurs when the weakened strain of the poliovirus used in OPV mutates and regains its ability to cause paralysis. This can happen if the virus circulates for an extended period in a population with low immunity, allowing it to evolve and become more virulent. VDPV is more likely to emerge in areas with poor sanitation and low vaccination coverage, where the weakened virus can spread more easily and mutate.

Since 2000, around 760 cases of vaccine-derived polio have been reported in 21 countries, a small number compared to the millions of lives saved by OPV. However, these cases highlight the need for ongoing vigilance and adaptation in vaccination strategies, particularly in regions where immunization rates are not optimal.

Despite being declared polio-free, India continues to run its Pulse Polio Immunisation Programme as a preventive measure. National Immunisation Days (NIDs) are conducted regularly, during which oral polio vaccines are administered to all children under the age of five. These mass immunization drives are crucial for maintaining high immunity levels in the population and preventing the reintroduction of the virus.

However, the emergence of vaccine-derived cases like the one in Meghalaya has sparked a debate over the continued use of OPV in India. Some experts argue that India should transition to using IPV exclusively, as it does not carry the risk of mutation and vaccine-derived cases. Others point out that OPV is still the most practical option for mass immunization campaigns in a country as large and diverse as India.

The recent case of vaccine-derived polio in Meghalaya serves as a reminder that the fight against polio is not over. While India has made tremendous progress in eradicating wild poliovirus, the challenge now lies in maintaining high immunity levels and preventing the emergence of vaccine-derived cases.

As India continues to suffer with this complex issue, it may be time to reconsider its vaccination strategy. Transitioning to IPV could eliminate the risk of vaccine-derived cases, but this approach would require significant investment in healthcare infrastructure and training. On the other hand, continuing with OPV allows for easy administration during mass immunization campaigns but carries the small risk of mutation.

Ultimately, the decision will depend on a careful evaluation of the risks and benefits, taking into account India’s unique demographic and logistical challenges. What is clear, however, is that vigilance is key. Continuous monitoring, rapid response to detected cases, and ongoing research into vaccine safety and efficacy will be essential in ensuring that India remains polio-free in the years to come.

The fight against polio is one of the most significant public health victories of the past century. However, the recent case in Meghalaya is a sobering reminder that the battle is not yet won. Vaccine-derived poliovirus represents a rare but real threat that requires ongoing attention and adaptation in our vaccination strategies.

India’s success in eradicating wild poliovirus is a testament to the power of collective action and sustained public health efforts. As the country moves forward, it must remain vigilant, ensuring that all children are vaccinated and that the risks associated with vaccination are carefully managed. Only through continued vigilance and adaptation can we ensure that future generations are free from the threat of polio.